Title:
USE OF AMHR2 RECOMBINANT PROTEIN OR FUSION PROTEIN IN PREPARATION OF DRUGS FOR TREATING AMH SIGNAL AXIS ABNORMAL ACTIVATION RELATED DISEASES
Document Type and Number:
WIPO Patent Application WO/2021/129362
Kind Code:
A1
Abstract:
The present invention provides a use of an AMHR2 recombinant protein or fusion protein in preparation of drugs for treating AMH signal axis abnormal activation related diseases, in particular, a use in preparation of AMH neutralizers or antagonists.
Inventors:
FU WENYAN (CN)
HU SHI (CN)
DING MIN (CN)
HU SHI (CN)
DING MIN (CN)
Application Number:
PCT/CN2020/134220
Publication Date:
July 01, 2021
Filing Date:
December 07, 2020
Export Citation:
Assignee:
PHARCHOICE THERAPEUTICS INC (CN)
International Classes:
A61K38/17; A61K47/68; A61P5/00; A61P15/08; A61P35/00
Domestic Patent References:
| WO2015114142A1 | 2015-08-06 | |||
| WO2015114142A1 | 2015-08-06 |
Foreign References:
| CN111000982A | 2020-04-14 |
Other References:
WANG YUPU, LIU GUOMIN; ZHAO ZHIWEI; WU JIANG: "The Research Progress and Application of Anti-Mullerian Hormone", SICHUAN JOURNAL OF ANATOMY, vol. 24, no. 4, 1 December 2016 (2016-12-01), pages 25 - 46, XP055824079, DOI: 10.3969/j.issn.1005-1457.2016.014.008
Attorney, Agent or Firm:
CHENGDU DINGFENG PATENT AGENCY (GENERAL PARTNER) (CN)
Download PDF: